Promotion

mRNA 15% OFF + Buy NTPs, get DNase I

View Now

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite

N2-isobutyryl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Guanosine-3'-CE-Phosphoramidite
Catalog No. PR2-002
CAS No. 150780-67-9
Purity HPLC≥98.0%
Molecular Formula C45H56N7O9P
Molecular Weight 869.94
Storage Condition -20℃

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite

N2-isobutyryl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Guanosine-3'-CE-Phosphoramidite
Grade
Amount/Package: 0.25g / 30mL screwed bottle-28
SKU: PR2-002-025A  |  suitable for  MerMade
Collections:  2'-O-Me Phosphoramidites Diagnostics Oligo Synthesis Phosphoramidites Phosphoramidites for Diagnostics Recommended Products Synthesis Blocks
Unit price:
$19.00

Price

$19.00
Taxes, discounts and Shipping calculated at checkout.
This variant is unavailable. Contact us if you have particular requirements.
Checkout

This Variant only supports customization. Please click the inquire button to submit a custom request.

Price/Order Inquiry

Shipping notes
Products on this site:
Currently ships to US and Canada.
For shipping worldwide, please contact us.
Order fulfillment: within 2 business days, if available.
US: 2-8 days (from CA by FedEx).
Canada: 5-10 days (excludes customs delays).

Details

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a isobutyryl (iBu) base-protecting group on guanine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

Applications

siRNA chemical modification

Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

Enzyme or structural RNA inhibition

Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

Features and Benefits

Delivers high coupling efficiency and consistently strong crude yields
Manufactured to ≥98% purity with tightly controlled impurity specifications
Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
Simplified purification: no special precautions needed against RNase degradation

Other Notes

  • Storage: Store in a dry, inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended
  • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
  • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

Reference

[1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

Specifications
  • Catalog No.
    PR2-002
  • CAS No.
    150780-67-9
  • SMILES
    CC(C)N(C(C)C)P(OCCC#N)O[C@H]1[C@@H](OC)[C@H](N(C=N2)C3=C2C(NC(NC(C(C)C)=O)=N3)=O)O[C@@H]1COC(C4=CC=C(OC)C=C4)(C5=CC=CC=C5)C6=CC=C(OC)C=C6
  • Molecular Formula
    C45H56N7O9P
  • Molecular Weight
    869.94
  • Appearance
    White powder
  • Purity
    HPLC≥98.0%
  • Storage Condition
    -20℃
  • Moisture Content
    K.F.≤0.20% w/w

Documentation
COA Contact Us

DMT-2'-O-Me-G(iBu)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a isobutyryl (iBu) base-protecting group on guanine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

Applications

siRNA chemical modification

Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

Enzyme or structural RNA inhibition

Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

Features and Benefits

Delivers high coupling efficiency and consistently strong crude yields
Manufactured to ≥98% purity with tightly controlled impurity specifications
Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
Simplified purification: no special precautions needed against RNase degradation

Other Notes

  • Storage: Store in a dry, inert atmosphere at -20 °C.
  • Coupling: 6 minute coupling time recommended
  • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
  • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

Reference

[1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

Why choose Hongene?

Trusted Partner in Nucleic Acid

Integrated Supply & Commercial Scale

With nearly 30 years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.

Proprietary Technology & IP

Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.

Rigorous Quality

We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.

Manufacturing Scalability

Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.

Global Business Network

Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

Global Business Distribution
40+
Countries & Regions
3000≈
Global Clients
54000+L
Annual NTP Production
58+t
Annual Amidites Production

Ask us anything!

Back to top

My Wishlist